The purpose of the study is to demonstrate that tirzepatide is superior to placebo for glycemic control; participants are randomly assigned to receive either tirzepatide or a placebo, and neither the participants nor the study staff know which treatment is being given.

The study lasts about 40 weeks, during which the assigned injection is taken each week and regular clinic visits are made to check blood sugar, weight, and safety. Blood sugar control is measured with a test called Hemoglobin A1c (HbA1c), which shows the average level of glucose in the blood over the past two to three months. Obesity and overweight describe a condition where body weight is higher than what is considered healthy for a person’s height.

This clinical trial is focused on studying Type 1 Diabetes in adults who are also overweight or have obesity. The treatment being tested is called tirzepatide (also known by its code name LY3298176), which is given as a solution for injection using a pre-filled pen. The purpose of the study is to see if tirzepatide can help control blood sugar levels better than a placebo.

Participants in the study will receive either tirzepatide or a placebo once a week. The study will last for about 40 weeks. During this time, the effects of tirzepatide on blood sugar levels will be closely monitored. The study aims to determine if tirzepatide is more effective than a placebo in managing blood sugar levels in people with Type 1 Diabetes.

This study is important for understanding how tirzepatide can help people with Type 1 Diabetes who are also dealing with being overweight or obese. The results could provide valuable insights into new treatment options for better managing blood sugar levels in these individuals.

During the study, the focus is on monitoring how the body responds to the new organ and the medications over the first year. This includes observing for signs of rejection, which occurs when the immune system identifies the transplanted organ as foreign and tries to destroy it. The study also tracks the occurrence of various infections and monitors how well the new pancreas functions by checking blood sugar levels and the need for insulin.

The purpose of the study is to explore whether this approach can improve insulin absorption and manage blood sugar levels more effectively. Participants will receive either the glucagon treatment or a placebo, and the study will monitor how their blood sugar levels respond over a short period. The treatment is administered subcutaneously, meaning it is injected just under the skin.

Throughout the study, various measurements will be taken to understand how the body processes insulin and glucagon. These include monitoring blood sugar levels and using special cameras and devices to assess how well the treatment is working. The study is expected to continue until the end of 2024, providing valuable insights into managing type 1 diabetes more effectively.

The study will use Colchicine Teva tablets that are modified into capsules containing 0.5 milligrams of the active medication. These capsules also contain microcrystalline cellulose, an inactive substance. Some participants will receive the active medication, while others will receive capsules containing only microcrystalline cellulose (placebo).

The treatment period will last 18 weeks, during which participants will take their assigned medication while continuing their regular diabetes care. Throughout the study, various measurements will be taken to monitor changes in the blood vessels of the eyes and to check kidney function through blood and urine tests. The study will also track how blood sugar levels change over time using continuous glucose monitoring devices worn by participants.

Participants in the study will be assigned to different groups to receive either the combination of both medications or Antithymocyte Globulin along with a placebo. During the course of the study, changes in the body’s ability to produce insulin will be monitored. This is measured by looking at levels of C-peptide, a substance produced by the body when insulin is made, often following a Mixed Meal Tolerance Test, which is a procedure used to see how the body reacts to consuming a meal.

Participants in the study will use an automated insulin delivery system, which is a technology that helps manage insulin levels automatically. During the study, individuals will receive a subcutaneous injection, meaning the medicine is injected just under the skin, before performing moderate exercise. The study examines how these medications affect blood sugar levels while performing continuous exercise approximately 90 minutes after eating a meal.

The purpose of this study is to examine how dapagliflozin and SC0062 work together compared to SC0062 alone in reducing the amount of a protein called albumin in the urine. When kidneys are damaged, they may leak albumin into the urine, and measuring this can show how well the kidneys are functioning. The study will also look at changes in body weight, blood pressure, kidney filtering ability, and markers that indicate fluid retention in the body. Additionally, the study will monitor any side effects that occur during treatment with these medications.

This is a crossover study, which means participants will receive different treatment combinations during different periods of the study. Each treatment period will last for 8 weeks. During the study, participants will take either SC0062 alone or a combination of both dapagliflozin and SC0062. Participants will need to continue managing their diabetes with insulin and monitoring their blood sugar levels at home as they normally do. Throughout the study, regular check-ups will be conducted to measure urine albumin levels, kidney function, and overall health to see how the treatments are working.

The purpose of this research is to evaluate how well the weekly insulin icodec controls blood sugar levels compared to daily insulin glargine in people with Type 1 Diabetes. The study will use pre-filled injection pens called FlexTouch to deliver the insulin medications under the skin. Participants will receive either weekly insulin icodec or daily insulin glargine for 26 weeks.

During the study, blood sugar control will be monitored through various measurements, including HbA1c (a blood test that shows average blood sugar levels over the past few months) and continuous glucose monitoring using a device called Dexcom G7. The study will also track other important factors such as the number of low blood sugar episodes and changes in body weight.

The main purpose of this study is to evaluate if this new treatment is safe for patients who have been recently diagnosed with Type 1 diabetes and still have some functioning insulin-producing cells. The treatment is given as a single intravenous injection of the modified cells back into the patient’s body.

During the study, patients will be monitored closely for any side effects and changes in their diabetes condition. The monitoring includes regular blood tests, checking blood sugar levels, and measuring how well the body is producing insulin. The study will track how the modified cells perform in the body and observe any changes in the patient’s need for insulin treatment over time.

During the study, participants take medication for four weeks. For the first two weeks, they take one tablet daily, followed by two tablets daily for the next two weeks. The study is designed so that participants receive both colchicine and placebo at different times, but neither they nor their doctors know which treatment they are receiving at any given time.

The main purpose is to determine if colchicine, when added to regular diabetes care, can help the body use insulin more effectively. The medication is being tested because some people with Type 1 diabetes have inflammation in their body that may make it harder for insulin to work properly. The study measures how well the body responds to insulin during treatment with colchicine compared to treatment with placebo.

The purpose of the study is to understand how blood platelets, which help with clotting, behave in people with Type 1 Diabetes compared to healthy individuals. The study will also look at the presence of plaques, which are fatty deposits in the arteries, and how they relate to blood clotting in people with diabetes. Participants will be observed over a period of time to see if aspirin affects these factors and if it can predict changes in artery health or the risk of heart disease.

Participants will be monitored for changes in their blood clotting and artery health, with some taking aspirin for at least seven days. The study will also investigate the relationship between blood clotting and inflammation, which is the body’s response to injury or infection, in people with Type 1 Diabetes. The trial aims to provide insights into how these factors might predict future health outcomes related to heart and blood vessel health.

The purpose of the study is to see if finerenone can help reduce a specific measure related to kidney function over a period of six months. Participants in the study will be randomly assigned to receive either finerenone or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The study will take place over several months, and participants will continue to receive their standard care for chronic kidney disease and type 1 diabetes while participating in the trial.

Throughout the study, researchers will monitor participants for any changes in their kidney function and any side effects that may occur. The main focus will be on changes in a specific kidney-related measure, and researchers will also keep track of any adverse events, including any significant increases in potassium levels, which is a potential side effect of the treatment. The study is designed to provide valuable information about the potential benefits and safety of finerenone for people with chronic kidney disease and type 1 diabetes.

The purpose of this research is to determine if mixing a small amount of glucagon with insulin can help the body absorb insulin more quickly after injection under the skin. The study will use a specially prepared solution that combines Lyumjev (a fast-acting insulin) with glucagon (a hormone that normally increases blood sugar) in specific amounts.

During the study, participants will receive subcutaneous injections of this combined insulin-glucagon solution. The solution contains 50 nanograms of glucagon for each unit of insulin. The treatment period will last up to two days, during which researchers will monitor how quickly the insulin works and how it affects blood sugar levels. The maximum daily dose of insulin will be 20 units, while the maximum amount of glucagon will be 0.5 micrograms.

Participants in the study will receive Desferal, which is given as an injection or infusion, meaning it is administered directly into the bloodstream. The study is designed to compare the effects of Desferal with a placebo, which is a substance with no active medication. This comparison helps researchers understand the true effects of Desferal. The study will follow a cross-over design, meaning participants will receive both Desferal and the placebo at different times during the study.

The main goal of the study is to determine if Desferal can improve the body’s response to hypoxia in patients with Type 1 Diabetes. This involves monitoring changes in certain cells and substances in the blood that are related to blood vessel growth and oxygen levels. The study will also look at various heart and lung functions to see how they are affected by the treatment. The trial is expected to continue until the end of 2026.

Participants in the study will be randomly assigned to receive either Verapamil SR or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for 12 months, during which participants will take the medication or placebo once daily by mouth. The main goal is to observe changes in the body’s ability to produce insulin in response to food intake over this period.

Throughout the study, participants will undergo regular check-ups and tests to monitor their health and the effects of the treatment. These tests will include measuring the levels of a substance called C-peptide, which indicates how well the body is producing insulin. The study will also track other health markers, such as blood sugar levels and insulin requirements, to gather comprehensive data on the potential benefits of Verapamil SR for people with Type 1 Diabetes.

The trial involves giving participants either Verapamil or a placebo in the form of oral capsules. The purpose of the study is to evaluate whether Verapamil can help maintain the function of the insulin-producing cells over time. Participants will be randomly assigned to receive either the medication or the placebo, and neither the participants nor the researchers will know who is receiving which treatment, a method known as “double-blind.”

Throughout the study, participants will have regular check-ups to monitor their health and the function of their insulin-producing cells. The study will last for several years, with the goal of understanding how **Verapamil** affects the progression of **Type 1 diabetes** in children. This research could potentially lead to new ways to manage the disease and improve the quality of life for those affected.

Participants in the study will undergo a special imaging process called PET/CT to measure how much of a substance called 68Ga-NODAGA-exendin is taken up by the pancreas. This will help researchers see the differences in beta cell mass before and after treatment, as well as compare results between those receiving the treatment and those receiving a placebo. The study will track these changes over a period of time to understand the effects of the treatments on the pancreas.

The study will involve regular imaging sessions to monitor changes in the pancreas, and these will be compared with other measurements related to insulin production, such as C-peptide and proinsulin levels. The goal is to gain insights into how these treatments might help preserve or improve the function of insulin-producing cells in people with Type 1 Diabetes.

Participants in the study will receive both medications at different times, allowing researchers to compare their effects. The study will last for a total of six months, during which participants will take one medication for a period and then switch to the other. Throughout the study, participants will be monitored for changes in ADHD symptoms, as well as any effects on their diabetes, such as blood sugar levels. The study will also track any side effects that may occur while taking these medications.

The goal is to determine which medication is more effective in managing ADHD symptoms while also considering the impact on diabetes control. This information will help doctors make better treatment decisions for children and teenagers who have both ADHD and Type 1 Diabetes. Participants will be closely observed by healthcare professionals to ensure their safety and well-being throughout the study.

The purpose of the study is to evaluate how the immune system responds to these treatments in patients who have recently been diagnosed with Type 1 Diabetes and still have some insulin production. Participants will first receive Ciclosporin for two months. Following this, they will receive ILT-101 or a placebo for a period of time. The study will monitor changes in the immune system, specifically looking at a type of white blood cell called Tregs, which play a role in regulating the immune response.

Throughout the study, participants will have regular check-ups to assess their health and monitor any changes in their condition. The study will track the evolution of insulin production and any side effects from the treatments. The goal is to understand how these treatments might help preserve insulin production and improve the management of Type 1 Diabetes in newly diagnosed patients.

Participants in the study will receive either sotagliflozin or a placebo, which is a tablet that looks like the medication but does not contain the active drug. The study will last for about three months, during which the effects of the medication on kidney health will be monitored. This will be done using a special imaging technique called MRI (Magnetic Resonance Imaging) to measure how well the kidneys are being supplied with oxygen. The goal is to see if sotagliflozin can improve kidney oxygenation compared to the placebo.

The study aims to provide valuable insights into how long-term use of sotagliflozin might help manage kidney health in people with Type 1 Diabetes and chronic kidney disease. By understanding these effects, researchers hope to find better ways to support kidney function and slow down the progression of kidney disease in these patients.

The study will involve taking Ladarixin in the form of a hard capsule, with a dosage of 400 mg taken twice a day. The treatment period will last for up to 12 months. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the medication. These check-ups will include various tests to assess how well the insulin-producing cells are functioning and to ensure the safety of the participants.

The main goal of the study is to determine if Ladarixin can help maintain the function of the insulin-producing cells in the pancreas and delay the worsening of Type 1 Diabetes. Additionally, the study will evaluate the safety of Ladarixin in this specific group of patients. Participants will be closely monitored for any changes in their condition and any potential side effects of the treatment. The study will provide valuable information on whether Ladarixin could be a beneficial treatment option for people with recent onset Type 1 Diabetes.

The purpose of the study is to evaluate how the treatment affects blood sugar control, which will be monitored using a method called Continuous Glucose Monitoring (CGM). Participants will take either domperidone or a placebo for a certain period, and their blood sugar levels will be tracked to see how much time they spend within a healthy range. The study will also look at other factors like the number of low blood sugar episodes and changes in insulin doses.

Throughout the study, participants will be asked to take the medication or placebo and return any unused capsules. The trial will gather information on various health aspects, including age, sex, and diabetes-related complications, to better understand the effects of the treatment. The study aims to provide insights into how domperidone can help manage blood sugar levels in people with Type 1 Diabetes and delayed stomach emptying.

The study compares two groups of participants – one receiving fenofibrate tablets and another receiving a placebo. The medication or placebo will be taken orally once daily at a dose of 160 mg for up to 52 weeks. Neither the participants nor their doctors will know which treatment they are receiving during the study period.

The main goal is to determine if fenofibrate can help maintain the remaining function of insulin-producing cells in the pancreas of young patients with newly diagnosed Type 1 Diabetes. Throughout the study, researchers will monitor various aspects of diabetes control, including blood sugar levels, insulin requirements, and markers of inflammation in the body. The study will also evaluate how safe and well-tolerated the medication is in young patients.

The purpose of the study is to observe how Verapamil SR affects the preservation of beta-cell function over a long period. Participants in the study will take 360 mg of Verapamil SR orally once a day. The study will last for 24 months, during which participants will have their beta-cell function measured at the start and at the end of the study. This will be done using a test called the mixed-meal tolerance test (MMTT), which helps assess how well the body is producing insulin. Some participants may have previously been treated with either a placebo or Verapamil SR for 12 months in a prior study.

Throughout the study, changes in blood glucose control, insulin requirements, and any severe low blood sugar episodes will be monitored. Additionally, the study will track any adverse events or changes in vital signs, such as heart rate and blood pressure, to ensure the safety of the participants. The study aims to provide valuable insights into whether Verapamil SR can help maintain insulin production in people with Type 1 diabetes, potentially leading to better management of the condition.

Participants in the study will receive either the ProTrans treatment or a placebo. The study is designed to be double-blinded, which means neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not influenced by expectations. The study will be conducted in two parts, with the first part involving a small group of participants to assess initial safety, followed by a larger group in the second part. The study will monitor participants over a period of time to evaluate how well the treatment works and to check for any side effects.

Throughout the study, various health parameters will be measured, such as insulin needs and blood sugar levels, to determine the treatment’s impact on managing Type 1 diabetes. The study aims to see if the treatment can help reduce the need for insulin and improve blood sugar control. Participants will be closely monitored for any adverse events, and the study will assess changes in specific markers related to diabetes management over time.

Participants in the study will receive one of the insulin treatments through a subcutaneous injection, which means the insulin is injected under the skin. The study will observe how these insulins affect blood sugar levels after meals and how they might influence the production of certain substances in the body that can cause stress to cells, known as reactive oxygen species. The study will also look at how the speed of stomach emptying affects blood sugar control with these insulins.

The trial will take place over a period of time, during which participants will be monitored to see how their blood sugar levels respond to the different insulin treatments. The study aims to provide insights into which insulin works best for people with Type 1 Diabetes, depending on how quickly their stomachs empty food. This information could help improve the management of blood sugar levels and reduce the risk of complications associated with high blood sugar.

The purpose of the study is to test a strategy of intensified care for people with Type 1 diabetes who are at high risk of cardiovascular disease. This involves setting ambitious treatment goals compared to standard care. The study will also investigate the safety and effectiveness of 40 mg of Finerenone in reducing the risk of cardiovascular death and hospitalization for heart failure. Participants will receive either the new treatment strategy or standard care, and some may receive a placebo. The study will last for a period of 60 weeks, during which participants will be monitored for any major adverse cardiovascular events, such as heart attacks or strokes, and hospitalizations for heart failure.

Throughout the study, researchers will assess whether the new treatment approach is more effective than standard care in preventing these cardiovascular events. They will also evaluate the impact on kidney function and overall mortality. The study aims to provide valuable insights into the potential benefits of these treatments for individuals with Type 1 diabetes who are at risk of cardiovascular complications.

The purpose of the study is to evaluate the safety and feasibility of administering Diamyd through injections into a lymph node in the groin area. Participants in the study will receive either two or three injections, spaced one month apart. The study is open to individuals aged 8 to under 18 years who have a specific genetic marker known as the HLA DR3-DQ2 haplotype and have multiple antibodies associated with Type 1 diabetes, indicating they are at increased risk for developing the disease.

The study aims to determine if this method of administering Diamyd is a viable option for preventing or delaying the onset of Type 1 diabetes in those at risk. Participants will be monitored to assess the safety of the treatment and to gather information on how well the treatment can be administered in this way. The study is expected to continue until September 2026.

The purpose of the study is to investigate how Alendronate affects markers related to bone health and blood sugar control in patients with diabetes. Participants will take the medication in the form of tablets, and the study will monitor changes in their bone and blood sugar markers over time. The study will last for a period of up to 24 months, during which participants will have regular check-ups to assess their health and the effects of the treatment.

Throughout the study, various health indicators will be measured, including HbA1c (a marker of blood sugar levels), bone density, and other substances in the blood that can provide information about bone and metabolic health. The study aims to provide insights into how Alendronate can benefit patients with diabetes who also have concerns about their bone health.

The study will involve participants receiving three doses of Diamyd over a period of time, with the goal of assessing its impact on the body’s ability to produce insulin and maintain blood sugar levels. Participants will be monitored for changes in their insulin production and blood sugar control over the course of the study. The study will also look at the safety of the treatment by tracking any side effects or reactions that occur during the trial.

In addition to Diamyd, the study will also involve the use of Divisun 2000 IE tabletter, which contains colecalciferol, commonly known as Vitamin D3. This is a vitamin supplement taken orally in tablet form. The study will last for a period of up to 24 months, during which participants will undergo regular assessments to monitor their health and the effects of the treatment. The overall aim is to determine if Diamyd can help preserve the body’s natural insulin production in people with newly diagnosed Type 1 Diabetes.

Participants in the study will be randomly assigned to receive either siplizumab or a placebo, which is a substance with no active medication. The study will last for 12 months, during which time the effects of the treatment on the participants’ diabetes will be closely monitored. The main focus will be on how well the insulin-producing cells are working after 12 weeks of treatment, with assessments continuing until the end of the study at week 52.

Throughout the study, participants will undergo various tests to measure changes in their diabetes management, including blood sugar levels and insulin use. The study will also track any side effects or health issues that may arise during the treatment period. This research aims to provide valuable insights into the potential benefits of siplizumab for people with newly diagnosed type 1 diabetes.

The purpose of the study is to assess the safety and effectiveness of Frexalimab in helping the pancreas continue to produce insulin in people who have recently been diagnosed with Type 1 diabetes. The study will last for a total of 104 weeks, which is about two years. During this time, participants will receive the treatment and be monitored regularly to see how their bodies respond. The study will include both adults and adolescents who are already on insulin therapy.

Throughout the study, participants will undergo various tests and assessments to measure how well their pancreas is functioning and how their diabetes is being managed. The goal is to see if Frexalimab can help maintain insulin production and improve overall diabetes management compared to those who receive a placebo. This research could provide valuable insights into new ways to support people with Type 1 diabetes in managing their condition more effectively.

The purpose of the study is to see if Grafalon can help prevent the loss of remaining insulin-producing cells in children and young adults who have been recently diagnosed with Type 1 diabetes. Participants in the study will receive either the Grafalon treatment or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, to ensure unbiased results.

Throughout the study, participants will be monitored over a period of time to assess how their bodies respond to the treatment. This includes regular check-ups and tests to measure the function of their insulin-producing cells and other health indicators. The study will help determine the best dosage of Grafalon for treating Type 1 diabetes in young patients and aims to provide valuable insights into managing this condition more effectively.

The purpose of the study is to see if getting the flu vaccine can help maintain the body’s ability to produce insulin in people with early Type 1 diabetes. Participants in the study will receive either the flu vaccine or a placebo. The study will track changes in the body’s ability to produce insulin over a period of 12 months. This will be measured by looking at levels of a substance called C-peptide, which indicates how well the pancreas is working. Other factors, such as blood sugar levels and insulin needs, will also be monitored.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the vaccine. The study aims to provide valuable information on whether the flu vaccine can be a helpful treatment in managing early Type 1 diabetes by preserving the function of insulin-producing cells.

The purpose of the study is to determine how colchicine affects levels of a protein in the blood called high-sensitivity C-reactive protein, which is a marker of inflammation. The study will last for 26 weeks, during which participants will take the medication or placebo orally in the form of tablets. Throughout the study, various health indicators will be monitored, including blood sugar levels, insulin usage, body weight, and cholesterol levels, to understand the broader effects of colchicine on health.

By the end of the study, researchers hope to gather valuable information on whether colchicine can be an effective treatment for reducing inflammation in people with Type 1 diabetes. This could potentially lead to new ways of managing the condition and improving the quality of life for those affected. The study is designed to be thorough and will carefully monitor participants’ health to ensure safety and gather accurate results.

The study will last for about a year, during which participants will receive regular injections and attend follow-up visits. Throughout the study, the researchers will monitor how well the body continues to produce insulin by measuring a substance called C-peptide, which is linked to insulin production. This will help determine if Ixekizumab is effective in maintaining insulin production in the body. Participants will also have their insulin dosage and blood sugar levels monitored to see how these change over the course of the study.

By the end of the study, the researchers aim to understand whether Ixekizumab can help people with newly diagnosed Type 1 Diabetes maintain their natural insulin production. This could potentially lead to better management of the disease and improve the quality of life for those affected. The study is expected to conclude by the end of 2028.